Agi Therapeutics was a specialty pharmaceutical company that was focused on the development and commercialisation of specialty drug products.The company completed an IPO in 2006 and was subsequently acquired by Vidara Therapeutics.
See more

Agi Therapeutics was a specialty pharmaceutical company that was focused on the development and commercialisation of specialty drug products.
The company completed an IPO in 2006 and was subsequently acquired by Vidara Therapeutics.

Covagen was a biotech company that developed a novel platform technology for the discovery and development of bispecific antibodies. The company was acquired by Janssen in 2014.
See more

Covagen was a biotech company that developed a novel platform technology for the discovery and development of bispecific antibodies. The company was acquired by Janssen in 2014.

Xention is a cardiovascular biotech company, specialised in the discovery and development of ion channel-modulating drugs. Its assets have now been partnered with or acquired by pharmaceutical partners.
See more

Xention is a cardiovascular biotech company, specialised in the discovery and development of ion channel-modulating drugs. Its assets have now been partnered with or acquired by pharmaceutical partners.

Precision Biotics (previously Alimentary Health) developed microbiome-based healthcare and nutritional products for inflammatory and other conditions.The company was acquired by Novozymes in June 2020.
See more

Precision Biotics (previously Alimentary Health) developed microbiome-based healthcare and nutritional products for inflammatory and other conditions.The company was acquired by Novozymes in June 2020.

Fusion Pharmaceuticals is a clinical-stage company focused on developing next-generation radiopharmaceuticals as precision medicines to treat cancer. The company is headquartered in Toronto with a base in Boston. Fusion listed on NASDAQ on June 2020 and now trades as FUSN. 
See more

Fusion Pharmaceuticals is a clinical-stage company focused on developing next-generation radiopharmaceuticals as precision medicines to treat cancer. The company is headquartered in Toronto with a base in Boston. Fusion listed on NASDAQ on June 2020 and now trades as FUSN. 

Prexton is a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease. The company was acquired by Lundbeck in March 2018.
See more

Prexton is a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease. The company was acquired by Lundbeck in March 2018.

Storm Therapeutics is a UK-based drug discovery company tackling oncology and other diseases through modulating RNA modifying enzymes. The company is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
See more

Storm Therapeutics is a UK-based drug discovery company tackling oncology and other diseases through modulating RNA modifying enzymes. The company is developing a unique platform to address these enzyme classes, including RNA methyltransferases.

Shorla Oncology is an Irish speciality pharma company developing new oncology therapeutic products. Shorla develops and commercializes innovative oncology drugs for cancer with a particular focus on women’s, pediatric and rare cancers.
See more

Shorla Oncology is an Irish speciality pharma company developing new oncology therapeutic products. Shorla develops and commercializes innovative oncology drugs for cancer with a particular focus on women’s, pediatric and rare cancers.

Coave Therapeutics is a French based clinical-stage biotech company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.Coave’s next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases. 
See more

Coave Therapeutics is a French based clinical-stage biotech company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.Coave’s next-generation AAV-Ligand Conjugate (‘ALIGATER’) platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases. 

Sibylla Biotech is based in Milan, Italy and develops a computational modelling platform to discover new protein degraders.Through their protein folding simulation technology platform, Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can …
See more

Sibylla Biotech is based in Milan, Italy and develops a computational modelling platform to discover new protein degraders.Through their protein folding simulation technology platform, Sibylla identifies relevant and previously inexplorable folding intermediates for protein targets that are currently considered undruggable in their native state. The company is developing a proprietary pipeline of small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.

Based in Germany, Complement Therapeutics is a cell & gene therapy company focused on addressing unmet needs in complement (important part of the immune system) mediated diseases. The lead asset is an AAV-2 gene therapy focused on blocking the lesions in dry age-related macular degeneration (dAMD). These lesions are a major cause of vision loss in patients. The company is …
See more

Based in Germany, Complement Therapeutics is a cell & gene therapy company focused on addressing unmet needs in complement (important part of the immune system) mediated diseases. The lead asset is an AAV-2 gene therapy focused on blocking the lesions in dry age-related macular degeneration (dAMD). These lesions are a major cause of vision loss in patients. The company is also exploring some earlier-stage programs.

Artica Therapeutics is a Dutch start-up biotech focused on the developement of insurmountable covalent compound to treat autoimmune disorders. The covalent approach essentially blocks the target in an irreversible manner with the aim of producing compounds with improved clinical efficacy.
See more

Artica Therapeutics is a Dutch start-up biotech focused on the developement of insurmountable covalent compound to treat autoimmune disorders. The covalent approach essentially blocks the target in an irreversible manner with the aim of producing compounds with improved clinical efficacy.

Subscribe to our Newsletter
* = required field